NEKTAR THERAPEUTICS·4

Sep 11, 9:01 PM ET

ROBIN HOWARD W 4

4 · NEKTAR THERAPEUTICS · Filed Sep 11, 2025

Insider Transaction Report

Form 4
Period: 2025-09-09
ROBIN HOWARD W
DirectorPresident & CEO
Transactions
  • Sale

    Common Stock

    2025-09-09$45.16/sh2,100$94,83653,908 total
  • Sale

    Common Stock

    2025-09-09$46.41/sh1,200$55,69252,708 total
  • Sale

    Common Stock

    2025-09-09$48.18/sh1,210$58,29849,342 total
  • Sale

    Common Stock

    2025-09-09$47.49/sh2,156$102,38850,552 total
Holdings
  • Common Stock

    (indirect: By Spouse)
    28
Footnotes (5)
  • [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  • [F2]This transaction was executed in multiple trades at prices ranging from $45.00 to $45.41 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
  • [F3]This transaction was executed in multiple trades at prices ranging from $46.05 to $46.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
  • [F4]This transaction was executed in multiple trades at prices ranging from $47.02 to $47.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
  • [F5]This transaction was executed in multiple trades at prices ranging from $48.00 to $48.57. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4